InMode's fortress balance sheet, with $396.2M cash and near-zero debt (D/E 0.01), provides a solid foundation, yet the company faces a decelerating revenue trajectory, with 2026Q2 revenue flat at $95.6M and a 6.2% decline in 2025. The asset-light model generat...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.35+1.2% vs $0.35 | $96M+0.7% vs $95M |
Q2 2026 May 6, 2026 | $0.25-16.1% vs $0.30 | $82M+2.7% vs $80M |
Q1 2026 Feb 10, 2026 | $0.46+10.5% vs $0.42 | $104M+2.3% vs $101M |
Q4 2025 Nov 5, 2025 | $0.38+8.3% vs $0.35 | $93M+2.5% vs $91M |
InMode (NASDAQ: INMD - Get Free Report) and IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Risk and Volatility InMode has a beta of 1.86,
IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- InMode Ltd.
InMode Ltd. (NASDAQ: INMD - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $14.26 and traded as high as $15.20. InMode shares last traded at $15.03, with a volume of 799,933 shares changing hands. Analyst Ratings
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Benchmark INMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for InMode Ltd. (INMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.19 | $815.65M | 9.92 | -6.16% | 25.33% | 13.53% | — | |
| $7.14 | $89.2M | -28.56 | 14.52% | -10.92% | -108.8% | — | |
| $19.80 | $985.81M | -12.22 | -23.72% | 1.13% | 1.08% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $398.30 | $140.71B | 50.61 | 20.51% | 28.45% | 17.71% | — | |
| $73.96 | $9.97B | 18.87 | 16.65% | 17.03% | 11.59% | — |
InMode Ltd. (INMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when INMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
InMode Ltd. (INMD) stock FAQ — growth, dividends, profitability & financials explained
InMode Ltd. (INMD) reported $374.6M in revenue for fiscal year 2025. This represents a 1523% increase from $23.1M in 2016.
InMode Ltd. (INMD) saw revenue decline by 6.2% over the past year.
Yes, InMode Ltd. (INMD) is profitable, generating $77.5M in net income for fiscal year 2025 (25.3% net margin).
InMode Ltd. (INMD) has a return on equity (ROE) of 13.5%. This is reasonable for most industries.
InMode Ltd. (INMD) generated $87.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
